Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from mesenchymal stromal cells derived from pediatric leukemia patients and healthy pediatric controls

ABSTRACT: B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow microenvironment, where they are protected against chemotherapeutic agents. Mesenchymal stromal cells (MSCs) are key components of this supporting framework. The present study aimed to unravel whether MSCs derived from pediatric BCP-ALL patients (leukemic MSCs) differ from MSCs derived from healthy pediatric donors (control-MSCs). Therefore, we studied their gene expression profiles.

ORGANISM(S): Homo sapiens

PROVIDER: GSE101425 | GEO | 2020/07/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data of mesenchymal stromal cells after 40 hours of co-culture with primary B-cell precursor acute lymphoblastic leukemia cells

Project description:B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells reside in the bone marrow microenvironment, where they are protected against chemotherapeutic agents. Mesenchymal stromal cells (MSCs) are key components of this supporting framework. The present study aimed to unravel whether MSCs derived from pediatric BCP-ALL patients (leukemic MSCs) differ from MSCs derived from healthy pediatric donors (control-MSCs). Therefore, we studied their gene expression profiles after 40 hours of co-culture with primary B-cell precursor acute lymphoblastic leukemia cells. MSCs were sorted using fluorescence-activated cell sorting (FACS).

2020-07-13 | GSE101454 | GEO

Targeted RNA-seq of BCP-ALL pediatric patients

Project description:Targeted RNA-seq of pediatric infant (<1year of age at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using a custom targeted panel for RNA analysis by NGS.

2021-10-25 | E-MTAB-9971 | biostudies-arrayexpress

Whole transcriptome analysis to detect fusion genes in pediatric BCP-ALL

Project description:Whole transcriptome RNA-seq of pediatric infant (<1year of aget at diagnosis) patients affected by B-cell precursor Acute Lymphoblastic leukemia (BCP-ALL). The aim of the study is to identify fusion gene rearrangements involved in childhood leukemia, using Next Generation Sequencing (NGS)

2021-10-25 | E-MTAB-9925 | biostudies-arrayexpress

Genome-wide analysis of basal gene expression analysis of pediatric acute lymphoblastic leukaemia xenograft cells

Project description:Analysis of patient-derived xenograft cells at the basal level. A panel of T- and BCP-ALL pediatric leukaemia xenograft cells were utilised to further understand the biology of pediatric leukaemia. Total RNA were isolated from patient-derived xenograft cells. Illumina beadchip HT12 were utilised

2015-04-01 | E-GEOD-63988 | biostudies-arrayexpress

Repurposing CD19-directed immunotherapies for pediatric t(8;21) acute myeloid leukemia

Project description:In contrast to patients with B cell precursor acute lymphoblastic leukemia (BCP-ALL), patients with acute myeloid leukemia (AML) have not yet benefited from recent advances in targeted immunotherapy. Repurposing immunotherapies that have been successfully used to target other hematological malignancies could, in case of a shared target antigen, represent a promising opportunity to expand the immunotherapeutic options for AML. Here, we evaluated the expression of CD19 in a large pediatric AML cohort, assessed the ex vivo AML killing efficacy of CD19-directed immunotherapies, and characterized the bone marrow immune microenvironment in pediatric AML, BCP-ALL, and non-leukemic controls. Out of 167 newly diagnosed de novo pediatric AML patients, 18 patients (11%) had CD19+ AML, with 61% carrying the translocation t(8;21)(q22;q22). Among CD19+ samples, we observed a continuum of CD19 expression levels on AML cells. In individuals exhibiting unimodal and high CD19 expression, the antigen was consistently present on nearly all CD34+CD38- and CD34+CD38+ subpopulations. In ex vivo AML-T cell co-cultures, blinatumomab demonstrated substantial AML killing, with an efficacy similar to BCP-ALL. In addition, CAR T cells could effectively eliminate CD19+ AML cells ex vivo. Furthermore, our immunogenomic assessment of the bone marrow immune microenvironment of newly diagnosed pediatric t(8;21) AML revealed that T- and NK cells had a less exhausted and senescent phenotype in comparison to pediatric BCP-ALL. Altogether, our study underscores the promise of CD19-directed immunotherapies for the treatment of pediatric CD19+ AML.

2024-08-08 | GSE270185 | GEO

Genome-wide analysis of basal gene expression analysis of pediatric acute lymphoblastic leukaemia xenograft cells

2015-04-01 | GSE63988 | GEO

Coagulation FXIII-A protein expression defines three novel sub-populations in pediatric B-cell progenitor acute lymphoblastic leukemia characterized by distinct gene expression signatures

Project description:Leukemic B-cell precursor (BCP) lymphoblasts were recently identified as a novel expression site for coagulation factor XIII subunit A (FXIII-A). The FXIII-A negative subgroup was significantly associated with the ‘B-other’ genetic category and had an unfavorable disease outcome RNA was extracted from bone marrow lymphoblasts of 42 pediatric patients with BCP-acute lymphoblastic leukemia (ALL). FXIII-A expression was determined by multiparameter FC. Genetic diagnosis was based on conventional cytogenetic method and fluorescence in situ hybridization. Affymetrix GeneChip Human Primeview array was used to analyze global expression pattern of 28869 well-annotated genes.

2019-11-19 | GSE134480 | GEO

MicroRNA-sequencing of Brazilian pediatric acute lymphoblastic leukemia

Project description:MicroRNA-sequencing of the bone marrow samples from Brazilian pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) and T-cell acute lymphoblastic leukemia (T-ALL).

2022-04-13 | E-MTAB-11621 | biostudies-arrayexpress

Targeted RNA-seq of BCP-ALL pediatric patients

Project description:Targeted RNA-seq of BCP-ALL pediatric patients

| PRJEB42250 | ENA

Persistence of targetable lesions, predicted therapy sensitivity and proteomes through disease evolution in pediatric acute lymphoblastic leukemia

Project description:This data set consists of pediatric acute lymphoblastic leukemia (ALL) primary bone marrow biopsies from the BC Children's Hospital BioBank, pediatric ALL cell lines, non-cancer bone marrow biopsies, and few ALL PDX. All files are DIA and searched by Spectronaut with a spectral library.

2023-01-05 | MSV000091012 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data